ASEP Medical Holdings Inc., together with its subsidiaries, focuses on developing diagnostic and therapeutic solutions for the treatment of sepsis. It offers peptide technology for therapeutic applications, including bacterial biofilm infections, anti-inflammatories, anti-infective immune-modulators, and vaccine adjuvants; diagnostic kits for predicting the onset of severe sepsis and organ failure; and coatings for medical devices. The company was formerly known as Trenchant Life Sciences Investment Corp. and changed its name to ASEP Medical Holdings Inc. in November 2021. ASEP Medical Holdings Inc. was incorporated in 2021 and is headquartered in Victoria, Canada.